How to Lose Weight Safely with W8MD

The safest way to lose weight is usually a medically supervised plan that combines reduced-calorie nutrition, increased physical activity, behavior changes, adequate protein, sleep evaluation and medication when medically appropriate.

Yes. W8MD helps patients create reduced-calorie diet plans that focus on protein, portion control, lower-glycemic foods, hydration, fiber and long-term sustainability rather than crash dieting.

Yes. W8MD encourages gradual increases in activity, walking, strength training and resistance exercises when appropriate. Physical activity helps improve insulin sensitivity, muscle preservation, energy, mood and weight maintenance.

Yes. W8MD can evaluate eligible patients for FDA-approved chronic weight-management medications, including Wegovy, Zepbound, Saxenda, Contrave, Qsymia, orlistat and Foundayo, depending on medical history, contraindications, insurance coverage, medication availability and treatment goals.

Yes. W8MD offers physician-supervised GLP-1 weight loss injection options for eligible patients. These may include semaglutide-based and tirzepatide-based options, along with brand-name medications when insurance coverage is available and criteria are met.

Yes. W8MD offers semaglutide-based weight-loss options when medically appropriate and available. W8MD can also help eligible patients pursue brand-name semaglutide products such as Wegovy when insurance coverage is available.

Yes. W8MD can evaluate eligible patients for Wegovy, the brand-name semaglutide medication used for chronic weight management. W8MD can help with dose planning, side-effect management, nutrition support and prior authorization documentation when insurance coverage is available.

Yes. W8MD can discuss Wegovy pill options for eligible patients who prefer an oral semaglutide weight-loss medication instead of injections. Medication access depends on labeling, availability, insurance coverage, cost and clinical appropriateness.

Yes. W8MD offers tirzepatide-based options when medically appropriate and available. Tirzepatide acts through GIP and GLP-1 pathways and may be considered for eligible patients needing chronic weight management support.

Yes. W8MD can evaluate eligible patients for Zepbound, the brand-name tirzepatide medication used for chronic weight management. W8MD can also help with prior authorization support when coverage is available.

Yes. W8MD can evaluate eligible adults with obesity and moderate-to-severe obstructive sleep apnea for Zepbound when clinically appropriate. W8MD also offers sleep apnea screening and convenient home sleep study options.

Yes. W8MD can evaluate eligible patients for Foundayo, an oral GLP-1 receptor agonist medication for chronic weight management, when clinically appropriate and available. W8MD can help compare Foundayo with Wegovy pill, Wegovy injection, Zepbound, Contrave, Qsymia and other options.

Yes. W8MD can evaluate eligible patients for Contrave, a prescription medication that combines naltrexone and bupropion. Contrave may be useful for selected patients with cravings, emotional eating or reward-driven eating, but it is not appropriate for everyone.

Yes. W8MD can evaluate eligible patients for Qsymia, a prescription medication that combines phentermine and topiramate. W8MD reviews blood pressure, heart history, mood history, pregnancy risk, medication interactions and side-effect risk before recommending this option.

Yes. W8MD can evaluate selected patients for phentermine when medically appropriate. Phentermine is not right for everyone and requires careful review of blood pressure, heart history, anxiety, insomnia, stimulant sensitivity and medication interactions.

Yes. W8MD can evaluate selected patients for topiramate when clinically appropriate. Topiramate may help some patients with cravings, night eating, migraine history or appetite control, but it requires medical supervision because of possible side effects and pregnancy-related risks.

Yes. W8MD can discuss orlistat for eligible patients who prefer a non-GLP-1 medication that works by reducing fat absorption. Patients using orlistat may need counseling about dietary fat intake, gastrointestinal side effects and fat-soluble vitamin supplementation.

Yes. W8MD can evaluate eligible patients for Saxenda, a daily injectable GLP-1 receptor agonist used for chronic weight management. Saxenda may be considered depending on age, prior medication history, coverage, availability and tolerability.

W8MD can provide Ozempic education and evaluate whether semaglutide-based treatment is appropriate. Ozempic is primarily a type 2 diabetes medication, while Wegovy is the semaglutide brand used for chronic weight management. W8MD can help patients understand the difference and choose the correct option.

Yes. W8MD can discuss Rybelsus for appropriate patients, especially those with type 2 diabetes who prefer oral semaglutide. Rybelsus is different from Wegovy pill, so W8MD helps patients understand the dosing, indication and expected role of each medication.

W8MD can provide Mounjaro education and evaluate tirzepatide-based treatment options. Mounjaro is the tirzepatide brand used for type 2 diabetes, while Zepbound is the tirzepatide brand used for chronic weight management and selected obstructive sleep apnea patients with obesity.

Yes. W8MD helps patients compare injectable GLP-1 medications, oral GLP-1 medications and traditional FDA-approved weight-loss medications based on medical history, weight-loss goals, food noise, cravings, diabetes status, sleep apnea risk, blood pressure, side effects, insurance coverage, cost and preference for pills versus injections.

Yes. W8MD offers affordable semaglutide-based and tirzepatide-based options when medically appropriate and available. Published starting options include semaglutide-based programs from $29.99 per week and up with insurance accepted for qualifying visits, or from $59.99 per week and up for self-pay patients. Tirzepatide-based options may start from $45.00 per week and up with insurance accepted for qualifying visits, or from $69.99 per week and up for self-pay patients. Pricing, dose, pharmacy availability, insurance coverage and eligibility vary.

Yes. W8MD accepts many insurance plans for qualifying medical visits. Medication coverage is separate and depends on the patient’s pharmacy benefit, diagnosis, prior authorization criteria, deductible, copay, plan exclusions and medication availability.

Yes. When coverage is available and criteria are met, W8MD can help document BMI, weight-related medical conditions, prior weight-loss attempts, medication history, sleep apnea, diabetes status, treatment response and medical necessity. Approval depends on the insurance plan.

Yes. W8MD offers sleep apnea screening and convenient home sleep study options. Sleep apnea can worsen fatigue, hunger, insulin resistance, blood pressure and weight regain, so W8MD often evaluates sleep health as part of long-term obesity care.

Yes. W8MD focuses on chronic weight management and long-term maintenance, not just short-term weight loss. Maintenance may include medication adjustment, nutrition support, protein planning, resistance training, sleep apnea treatment, relapse prevention and follow-up.

W8MD’s active offices are in Brooklyn / New York City and Northeast Philadelphia. The Brooklyn office phone number is 718-946-5500. The Philadelphia office phone number is 215-676-2334.